ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...
The evolution of genitourinary cancer treatment includes a shift from monotherapies to combination therapies, improving survival and quality of life. Combining androgen blockers with DNA repair ...
The AMPLITUDE trial showed Zejula's efficacy in extending progression-free survival in metastatic hormone-sensitive prostate cancer with HRR gene defects. Achieving a PSA level below 0.2 in prostate ...
Incorporating Molecular Data Into Treatment Decision Making in Gastroesophageal and Pancreaticobiliary Cancers: Timing and Strategies Palliative care (PC) plays a critical role in managing the ...
Changes in perception of immunotherapy over time among patients with advanced genitourinary cancers.
Characteristics associated with common reasons to pursue genomic profiling among patients with metastatic genitourinary cancers. This is an ASCO Meeting Abstract from the 2022 ASCO Genitourinary ...
RNA originating from genitourinary tract tissues is resolvable at cell-type resolution in human urine. Study: Deconvolution of Human Urine across the Transcriptome and Metabolome. Image Credit: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback